Finanzen von Intra-Cellular Therapies Inc (ITCI)ITCIIntra-Cellular Therapies Inc

Evaluating the bottom line, Intra-Cellular Therapies Inc maintains a gross margin of 89.76%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -14.66%, while the net margin is -8.48%. These profitability ratios, combined with a Return on Equity (ROE) of -8.58%, provide a clear picture of how effectively ITCI converts its operational activities into shareholder value.

In the context of the broader market, ITCI competes directly with industry leaders such as INSM and UTHR. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, ITCI's gross margin of 89.76% stands against INSM's 83.71% and UTHR's 87.30%. Such benchmarking helps identify whether Intra-Cellular Therapies Inc is trading at a premium or discount relative to its financial performance.